New Two-Pronged attack on lung cancer enters human testing
NCT ID NCT02609776
Summary
This is the first study in people for a new drug called Amivantamab, designed to fight advanced non-small cell lung cancer by targeting two specific proteins on cancer cells. The main goals are to find safe doses when given alone, with another drug (lazertinib), or with standard chemotherapy, and to see early signs of whether it helps control the cancer. It is for adults whose cancer has continued to grow despite previous treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Duarte, California, United States
-
Study site
La Jolla, California, United States
-
Study site
Orange, California, United States
-
Study site
Santa Monica, California, United States
-
Study site
West Hollywood, California, United States
-
Study site
Tampa, Florida, United States
-
Study site
Chicago, Illinois, United States
-
Study site
Bethesda, Maryland, United States
-
Study site
Boston, Massachusetts, United States
-
Study site
Detroit, Michigan, United States
-
Study site
Rochester, Minnesota, United States
-
Study site
St Louis, Missouri, United States
-
Study site
New York, New York, United States
-
Study site
Portland, Oregon, United States
-
Study site
Philadelphia, Pennsylvania, United States
-
Study site
Houston, Texas, United States
-
Study site
Fairfax, Virginia, United States
-
Study site
Camperdown, Australia
-
Study site
Heidelberg, Australia
-
Study site
Kogarah, Australia
-
Study site
Murdoch, Australia
-
Study site
Woolloongabba, Australia
-
Study site
Toronto, Ontario, Canada
-
Study site
Beijing, China
-
Study site
Changchun, China
-
Study site
Changsha, China
-
Study site
Chengdu, China
-
Study site
Chongqing, China
-
Study site
Guangzhou, China
-
Study site
Hangzhou, China
-
Study site
Hefei, China
-
Study site
Nanchang, China
-
Study site
Nanjing, China
-
Study site
Wuhan, China
-
Study site
Zhengzhou, China
-
Study site
Bordeaux, France
-
Study site
Dijon, France
-
Study site
Lyon, France
-
Study site
Marseille, France
-
Study site
Paris, France
-
Study site
Saint-Herblain, France
-
Study site
Villejuif, France
-
Study site
Chūōku, Japan
-
Study site
Hyōgo, Japan
-
Study site
Kashiwa, Japan
-
Study site
Kurume, Japan
-
Study site
Nagoya, Japan
-
Study site
Niigata, Japan
-
Study site
Osaka, Japan
-
Study site
Tokyo, Japan
-
Study site
Wakayama, Japan
-
Study site
Yonago, Japan
-
Study site
Cheongju-si, South Korea
-
Study site
Goyang-si, South Korea
-
Study site
Incheon, South Korea
-
Study site
Seongnam-si, South Korea
-
Study site
Seoul, South Korea
-
Study site
A Coruña, Spain
-
Study site
Barcelona, Spain
-
Study site
Madrid, Spain
-
Study site
Málaga, Spain
-
Study site
Santander, Spain
-
Study site
Seville, Spain
-
Study site
Kaohsiung City, Taiwan
-
Study site
Taichung, Taiwan
-
Study site
Taipei, Taiwan
-
Study site
Manchester, United Kingdom
-
Study site
Newcastle upon Tyne, United Kingdom
-
Study site
Sutton, United Kingdom
Conditions
Explore the condition pages connected to this study.